Immunoblotting of tumor lysates showed an obvious reduction in MCL-1 levels in the MCL-1 knockdown group, but little effect on AKT/ HIF-1α pathway molecules while compared with vehicle treatment group, suggesting that MCL-1 acts as a downstream factor in the AKT/ HIF-1α signaling pathway. The gene discussed is MCL1; the disease is neoplasm.